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Abstract
Background: The function of the right and left ventricles is intimately related through a shared septum and
pericardium. Therefore, right ventricular (RV) disease in pulmonary hypertension (PH) can result in abnormal
left ventricular (LV) myocardial mechanics. To assess this, we implemented novel cardiovascular magnetic
resonance (CMR) tissue phase mapping (TPM) to assess radial, longitudinal and tangential LV myocardial
velocities in patients with PH.
Methods: Respiratory self-gated TPM was performed using a rotating golden-angle spiral acquisition with
retrospective cardiac gating. TPM of a mid ventricular slice was acquired in 40 PH patients and 20 age- and
sex-matched healthy controls. Endocardial and epicardial LV borders were manually defined, and myocardial
velocities calculated using in-house software. Patients without proximal CTEPH (chronic thromboembolic PH)
and not receiving intravenous prostacyclin therapy (n = 34) were followed up until the primary outcome of
disease progression (death, transplantation, or progression to intravenous therapy) or the end of the study.
Physicians who determined disease progression were blinded to CMR data. Conventional ventricular volumetric indices
and novel TPM metrics were analyzed for prediction of 6-min walk distance (6MWD) and disease progression.
Results: Peak longitudinal (p < 0.0001) and radial (p = 0.001) early diastolic (E) wave velocities were significantly
lower in PH patients compared with healthy volunteers. Reversal of tangential E waves was observed in all
patients and was highly discriminative for the presence of PH (p < 0.0001).
The global radial E wave (β = 0.41, p = 0.017) and lateral wall radial systolic (S) wave velocities (β = 0.33, p = 0.028)
were the only independent predictors of 6MWD in a model including RV ejection fraction (RVEF) and LV stroke volume.
Over a median follow-up period of 20 months (IQR 7.9 months), 8 patients commenced intravenous therapy and 1
died. Global longitudinal E wave was the only independent predictor of clinical worsening (6.3× increased
risk, p = 0.009) in a model including RVEF and septal curvature.
Conclusions: TPM metrics of LV diastolic function are significantly abnormal in PH. More importantly, abnormal LV E
wave velocities are the only independent predictors of functional capacity and clinical worsening in a model that
includes conventional metrics of biventricular function.
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Background
Pulmonary hypertension (PH) is characterized by in-
creased pulmonary artery pressure and right ventricular
(RV) failure. Cardiovascular magnetic resonance (CMR)
is the reference standard method of assessing RV func-
tion and is now routinely used in PH. Several studies
have shown that CMR-derived RV volumes and ejection
fraction (EF) are prognostic in this condition [1, 2].
It has also been shown that left ventricular ejection
fraction (LVEF) is reduced in late stage PH [3]. However,
the majority of PH patients have normal LVEF, and LV
function is not prognostic [2]. Nevertheless, it is likely
that these patients do have abnormal LV mechanics due
to ventricular interdependence [4–8]. This could result
in additional functional deficits, as is the case in patients
with RV failure due to congenital heart disease [9]. Con-
sequently, assessment of LV myocardial mechanics may
be clinically useful in this patient population.
The most comprehensive way of evaluating LV me-
chanics is to assess the regional and geometric compo-
nents of LV motion. There are several CMR methods
that can be used to assess these metrics. In this study,
we used tissue phase mapping (TPM) to assess radial,
longitudinal and tangential myocardial velocities in pa-
tients with PH [10–13]. As this type of evaluation has
not been performed in this population before, it is of un-
certain clinical value. Therefore, our general aim was to
explore the utility of TPM measures of LV myocardial
mechanics in patients with PH.
The specific aims of this feasibility study were: i) to as-
sess global and regional LV myocardial mechanics in
healthy volunteers and in patients with PH with pre-
served LVEF, ii) to determine the relationship between
myocardial velocities and exercise capacity, and iii) to
test the ability of myocardial velocities to predict clinical
worsening.
Methods
Study population
The study population consisted of 40 consecutive pa-
tients with PH and 20 healthy volunteers. Inclusion
criteria for patients were: i) PH diagnosed by right
heart catheterization (mean pulmonary artery pressure
(mPAP) >25 mmHg and pulmonary capillary wedge
pressure (PCWP) <15 mmHg) [14]; or ii) presentation
for routine out-patient clinical evaluation with known
PH, and/or right heart catheterization for diagnosis or
follow-up of PH. Exclusion criteria for patients were:
i) left-sided cardiac disease unrelated to PH (including
ischemic heart disease, LV dysfunction or hypertrophy,
and left-sided valve disease); ii) clinically significant re-
strictive or obstructive lung disease identified by pulmon-
ary function tests; iii) arrhythmia; or iv) contraindications
to CMR. Exclusion criteria for healthy volunteers were: i)
past medical history of cardiovascular disease (including
hypertension); ii) history of cardiac medications; iii)
arrhythmia; or iv) contraindications to CMR.
All patients underwent the CMR study between 3rd
October 2012 and 24th November 2013. All partici-
pants were imaged using a 1.5T MR scanner (Magnetom
Avanto, Siemens Healthcare, Erlangen, Germany). All pa-
tients underwent a 6-min walk distance test (6-MWD).
Twenty-nine patients (73 %) underwent clinically indi-
cated right heart catheterization within 40 days of CMR
(median 8 days, IQR 12 days).
The local institutional research ethics committee (North
West London REC 2) approved the study and informed
written consent was obtained from all participants.
Conventional CMR protocol and image processing
Biventricular volumetric data were obtained as de-
scribed previously, using a radial k-t SENSE real-time
sequence [15], with contiguous transaxial and short-
axis ventricular stacks acquired for RV and LV
analyses respectively. Through-plane flow data were
acquired in the ascending aorta, right and left branch
pulmonary arteries, and for mitral valve inflow, using a
velocity-encoded, prospectively-triggered spiral PCMR se-
quence [16].
All images were processed using in-house plug-ins for
the open source OsiriX DICOM software platform
(OsiriX Foundation, Geneva, Switzerland) [17]. Endocar-
dial borders were traced manually at end-diastole and
end-systole of both ventricles to assess biventricular
function. This allowed evaluation of end diastolic vol-
ume (EDV) and end systolic volume (ESV), and calcula-
tion of stroke volume (SV) and ejection fraction (EF)
[15]. Aortic and pulmonary artery flow were measured
from the PCMR data, which were segmented using a
semi-automatic vessel edge detection algorithm with
manual operator correction [18]. Transmitral E and A
wave peaks were measured from the mitral valve inflow
PCMR data, allowing calculation of E/A ratio. Septal
curvature was assessed using the midventricular short
axis cine images, as described previously [19].
Tissue phase mapping protocol and image processing
Myocardial velocities were acquired using a respiratory
self-navigated, cardiac gated, velocity encoded golden-
angle spiral sequence [13]. To summarize, a two-sided
flow-encoding scheme (with positive and negative bipo-
lar pulses applied for each velocity-encoding direction)
was used to enable high temporal-resolution imaging
(rather than conventional one-sided flow-encoding
where four flow-encoded readouts are required). Data
were continuously acquired, with each consecutive flow-
encoding couplet rotated by the golden-angle. Consecu-
tive spiral pairs (10 in each window) are combined to
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produce low temporal resolution (315 ms) real-time
images. These real-time data are used to create an
image based respiratory navigator, used to select 30 %
of the expiratory spiral interleaves for the final retro-
spectively cardiac-gated reconstruction. Sequence pa-
rameters: TE/TR 3.85/14.9 ms, FOV 450 mm, Matrix:
384 × 384, uniformly distributed spiral interleaves re-
quired to fill k-space: 30 (for each of the three phase-
encoded directions), slice thickness: 7 mm, VENC:
30 cm/s, Flip angle: 25°, pixel bandwidth: 930 Hz/pixel.
This achieved a temporal resolution of 27.14 ms, with
a spatial resolution 1.17 × 1.17 mm, giving approxi-
mately 40 cardiac phases. The nominal scan time, as-
suming a heart rate of 60 bpm and 100 % respiratory
efficiency, would be 1 min 30 s, resulting in a scan
time of approximately 4 to 5 min per subject depend-
ing upon heart rate. TPM data were acquired in mid-
ventricular short-axis, which was chosen by reference
to a 4-chamber cine at end-systole.
This sequence does not include any black blood pulses
(as conventionally used in TPM) as this would have dis-
rupted the continuous acquisition of data necessary for
calculation of the respiratory navigator and retrospective
cardiac gating. No off-resonance correction was per-
formed as this would have increased the scan time or re-
duced the temporal resolution of the scan. Some minor
image blurring was observed around fat tissue, but this
did not severely affect the velocity measurements as the
fat was generally spatially separated from the myocar-
dium. Background phase offsets were minimized in the
TPM data by optimizing the flow gradients and correct-
ing for Maxwell terms. This resulted in no observable
background phase offsets in the data.
All images were processed using an in-house plug-in
for OsiriX [17]. For each dataset, endocardial and epi-
cardial ventricular borders were manually segmented
on the magnitude images to create a ventricular region
of interest (ROI). The ventricular ROI was further split
into four segments: septal, anterior, lateral and inferior.
Bulk motion correction was performed [20], before
transformation of the in-plane velocities to an internal
polar coordinate system positioned at the center-of-
mass of the LV. This allowed motion to be described in
terms of radial (Vrad), tangential (Vtang) and longitu-
dinal (Vlong) velocities [21]. For each direction, global
velocities were calculated by averaging the velocity in a
given direction (radial, longitudinal and tangential)
within the ventricular ROI in each frame. Regional vel-
ocities were calculated by averaging the velocities in
each segment. Peak systolic (S wave) and early diastolic
(E wave) values were quantified from the longitudinal,
radial and tangential velocity-time curves. The tangen-
tial S (S1 and S2) and E (E1 and E2) wave peaks were
biphasic. Vector field plots and color-coded position-
time maps were generated for each myocardial velocity
component to allow easy visualization of the results.
Statistics
STATA 13 was used for statistical analyses. Data were
examined for normality using the Shapiro-Wilk test.
Descriptive statistics are expressed as mean ± standard
deviation (SD) when normally distributed and median
(inter-quartile range, IQR) when non-normally distrib-
uted. Proportions are expressed as percentages.
Independent samples t-tests with Welch’s correction
for unequal variances were used to compare paramet-
ric data in PH patients and controls (n = 11). The
Mann–Whitney-U test was used for non-parametric
data (n = 9). Fisher’s exact test was used to compare
proportions data (n = 3). For subgroup analysis, PH
patients were divided into 3 groups: PH associated
with connective tissue disease (CTD), PH not associ-
ated with CTD, and chronic thromboembolic PH
(CTEPH). The Kruskal-Wallis test was used to test
for equality of abnormal global myocardial velocities
(n = 5) between the different sub-groups of PH. The
group of tests comparing normal controls to patients
was considered a single family of statistical inferences
and the familywise error rate was controlled using
Bonferroni correction. Specifically, we adjusted for 28
statistical comparator tests resulting in a corrected
critical p-value of <0.0018.
Random-effects generalized least squares models were
used to compare myocardial velocities in the four myo-
cardial segments. Interaction terms for the myocardial
segment and presence of disease were included in the
models. This analysis was only performed if the global
velocities were abnormal (Erad, Elong, S2tang, E1tang, and
E2tang). In addition, this analysis was used to assess the
timing of the Erad peak, which on visual inspection ap-
peared to vary between segments. Bonferroni correction
was required to control the familywise error rate in this
group of 6 generalized least squares models, and the ad-
justed critical p-value was 0.0083.
To assess the relationships between abnormal myocar-
dial velocities and hemodynamic parameters a 2-stage
procedure was employed. Firstly, simple univariate ana-
lysis was performed using Pearson’s correlation coeffi-
cient. This allowed selection of the conventional CMR
biventricular parameters and afterload metrics with the
strongest correlation to the abnormal myocardial veloci-
ties. To identify independent predictors of myocardial
velocity these variables were entered into random-effects
generalized least squares models. Variables in this model
with a p-value of <0.05 were considered statistically
significant.
A similar 2-stage analysis was performed to assess the
relationship between 6-MWD and CMR data. From the
Knight et al. Journal of Cardiovascular Magnetic Resonance  (2015) 17:116 Page 3 of 11
univariate analysis, the strongest correlating E and S
wave peaks and conventional CMR metrics were iden-
tified. These were then entered into a multiple linear
regression model to determine covariates that were
independently associated with 6-MWD. Variables in
this model with a p-value of <0.05 were considered
statistically significant.
All patients were followed up until death, transplant-
ation, progression to intravenous epoprostenol, or the
end of the study (February 25th, 2015). The decision to
list a patient for transplantation or commence intraven-
ous vasodilator therapy was based upon clinical assess-
ment of deterioration in functional class and/or cardiac
catheterization derived hemodynamic data. CMR data
were not used in these management decisions and the
physicians involved in the patients’ care were blinded to
the CMR results. Univariate Cox proportional hazards
analysis was used to assess the predictive ability of all
CMR variables in the 34 patients without proximal
CTEPH and not treated with intravenous epoprostenol.
The primary outcome was freedom from death, trans-
plantation or progression to intravenous therapy. The E
and S waves and conventional CMR metrics with the
greatest hazard ratios were entered into a multivariable
Cox proportional hazards analysis to determine which
covariates were independent predictors of clinical
worsening. A p-value of <0.05 was taken as statisti-
cally significant.
Results
Study population characteristics
There was no difference in the age distribution of
PH patients and normal controls (50 years (IQR: 45–
59 years) versus 47 years (IQR: 42–54 years) respect-
ively, p = 0.30). Thirty-out-of-forty patients were fe-
male compared to 16 out of 20 controls (p = 0.76).
Patient characteristics and underlying diagnoses are
detailed in Table 1. The largest patient sub-group
had PH associated with CTD (20/40), the next lar-
gest sub-group (12/40) had PH not associated with
CTD (10/12 had idiopathic PAH), followed by pa-
tients with CTEPH (8/40). All patients were normo-
tensive at the time of the study with a median
systolic BP of 110 mmHg (IQR: 105–120 mmHg) and
a mean diastolic BP of 72 ± 11 mmHg. Thirty-two pa-
tients were receiving PH therapy at the time of CMR
study (Table 1).
Conventional CMR metrics from normal subjects
and PH patients are shown in Table 2. In PH, the RV
was dilated with reduced RVEF and the LV was com-
pressed with reduced SV. In addition, septal curvature
was lower (or reversed in 65 % of patients). Neverthe-
less, LVEF and E/A ratio were not significantly differ-
ent between patients and controls.
Median 6-MWD in PH patients was 372 m (IQR:
286–450 m). Twenty-nine PH patients underwent
clinically indicated right heart catheterization within
40 days of CMR (median 8 days, IQR 12 days).
Median pulmonary vascular resistance (PVR) was
523 dyn · s/cm5 (IQR 402–717 dyn · s/cm5) and aver-
age mPAP was 46 ± 13 mmHg. All patients had a
PCWP < 15 mmHg.
Table 1 Patient characteristics
Etiology [33] Number (%)
1. PAH 11 (28)
- 1.1 Idiopathic 10
- 1.2 Heritable 1
1.4 Associated with (APAH): 21 (53)
- 1.4.1 CTD 20
- Limited cutaneous systemic sclerosis 13
- Diffuse cutaneous systemic sclerosis 2
- Systemic lupus erythematosus 3
- Sjögren’s syndrome 1
- Mixed CTD 1
- 1.4.3 Portal Hypertension 1
4 CTEPH 8 (20)
- Proximal (operable) 5
- Distal (inoperable) 3
Right Heart Catheterization (RHC) data (n = 29)
Time interval between CMR and RHC (days) 8 (IQR 12)
Mean pulmonary artery pressure (mPAP, mmHg) 46 ± 13
Pulmonary vascular resistance (PVR, dyn · s/cm5) 523 (IQR 402–717)
World Health Organization class (%)
I 1 (2.5)
II 14 (35)
III 22 (55)
IV 3 (7.5)
6-MWD (metres) 372 (IQR 286–450)
Vasodilator therapy
Phosphodiesterase type 5 inhibitor 28 (70)
Endothelin receptor antagonist 22 (55)
Intravenous prostacyclin 1 (3)
Treatment naive 8 (20)
Oral monotherapy 14 (35)
Dual combination oral therapy 16 (40)
Triple combination therapy 1 (3)
Additional PH therapies
Oral prostacyclin 1 (3)
Inhaled prostacyclin 1 (3)
Tyrosine-kinase inhibitor 2 (5)
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Myocardial velocities in normal subjects and PH patients
Myocardial velocities were acquired successfully in all
subjects. Figure 1 shows representative LV velocity vec-
tors in a normal subject and a PH patient.
Global myocardial peak velocities in normal subjects
and PH patients are summarized in Table 3. Patients
with PH had reduced LV peak Erad, Elong and S2tang
velocities, with reversal and significant change in both
Etang peaks. This can be appreciated in Fig. 2, which
shows representative global radial, longitudinal, and
tangential velocity curves from a normal subject and
a PH patient. Reversal of both Etang waves was highly
discriminatory for the presence of PH. All patients
had a reversed E1tang compared to 4/20 normal sub-
jects (p < 0.0001), while 32/40 patients had a reversed
E2tang compared to 2/20 normal subjects (p < 0.0001).
The magnitude of all abnormal global myocardial velocity
peaks did not differ between etiological groups (p > 0.59).
Table 2 CMR characteristics of control subjects versus patients
with PH
Normal PH patient p-value
RVEDV (mL) 130 (104–156) 158 (128–204) 0.0056
RVESV (mL) 38 (31–63) 103 (70–133) <0.00001*
RVSV (mL) 87 (74–99) 62 (48–75) 0.0006*
RVEF 65 ± 8 40 ± 12 <0.00001*
LVEDV (mL) 134 (108–139) 88 (74–109) 0.0001*
LVESV (mL) 42 ± 16 32 ± 13 0.012
LVSV (mL) 85 ± 19 62 ± 18 <0.00001*
LVEF 67 ± 8 66 ± 9 0.61
LV cardiac output (L/min) 5.6 (4.8–6.4) 4.6 (3.8–5.5) 0.0094
Septal curvature 1.09 ± 0.10 −0.20 ± 0.58 <0.00001*
E/A ratio 1.56 (1.23–2.88) 1.33 (1.11–2.36) 0.31
Values are mean ± SD, or median (interquartile range)
*indicates statistical significance (p < 0.0018 following Bonferroni correction)
Fig. 1 LV velocity vector plots from a healthy volunteer and a PH patient at four time points in the cardiac cycle (indicated by the ECG trace). The
line colors represent longitudinal velocities: blue or yellow/red represent myocardial motion towards or away from the apex respectively. The line
orientation and length represents the vector sum of the radial and tangential velocities. Note the biphasic tangential systolic (S1 and S2) and
early diastolic (E1 and E2) motions. In health, this follows an anti-clockwise then clockwise motion in systole and diastole. In PH, however, there is
reversal of early diastolic tangential untwisting directions: clockwise untwisting occurs prior to anti-clockwise untwisting
Table 3 Peak global myocardial velocities in control subjects
versus patients with PH
Global velocity Normal (cm/s) PH patient (cm/s) p-value
LV Srad 2.4 ± 0.4 2.3 ± 0.5 0.14
LV Erad 3.1 ± 0.5 2.3 ± 1.0 0.001*
LV Slong 3.3 ± 1.0 3.3 ± 1.1 0.98
LV Elong 4.2 (3.4, 5.5) 2.6 (1.7, 3.3) <0.00001*
LV S1tang −1.8 ± 0.7 −1.4 ± 0.8 0.064
LV S2tang 1.3 ± 0.6 0.50 ± 0.69 0.0001*
LV E1tang −0.4 ± 0.6 1.4 ± 0.5 <0.00001*
LV E2tang 0.9 (0.7,1.3) −0.8 (−1.1, −0.3) <0.00001*
Values are mean ± SD, or median (interquartile range)
*indicates statistical significance (p < 0.0018 following Bonferroni correction)
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Regional variations in normal subjects and PH patients
Figure 3a shows radial LV myocardial velocities as a
function of position and time in a normal subject and a
patient with PH. In patients, there was a trend to-
wards Erad velocity peaking in the anterior segment
first (approximately 80 ms, p = 0.026) as seen in Fig. 4.
However, there was no significant regional difference
in the magnitude of the Erad peaks (p > 0.07).
Longitudinal velocity maps are shown in Fig. 3b. In
normal subjects, Elong peak velocity was similar in the
inferior wall and septum (p = 0.88) but higher in the
anterior (p = 0.008) and lateral walls (p < 0.001). However,
in patients, this regional variation was less distinct (Fig. 4)
with only a trend towards higher Elong peak in the lateral
segment (p = 0.012).
Figure 3c shows tangential velocity maps in a normal
subject and patient. There were no regional variations in
tangential velocity peaks in controls or patients.
Hemodynamic correlates with myocardial velocities
Univariate hemodynamic correlates with abnormal global
myocardial velocities are shown in Table 4. Both peak Erad
and Elong strongly correlated with mPAP, RVESV and E/A
ratio. In addition, peak Erad also correlated with LVSV.
The first global Etang peak only correlated with
RVESV (r = 0.35, p = 0.023). The second Etang and
Stang peaks did not correlate with any of the tested
metrics (p > 0.1). In a generalized least squares model
that included mPAP, RVESV, LVSV and E/A, only RVESV
was independently predictive of either longitudinal or
radial E wave velocities (β = −0.43, p = 0.001).
Functional correlates with myocardial velocities
All correlates with 6-MWD are shown in Additional
file 1: Table S1. The strongest E wave myocardial vel-
ocity correlate with 6-MWD was the global Erad peak
(r = 0.58, p = 0.0001). The strongest S wave myocardial
velocity was the lateral Srad peak (r = 0.48, p = 0.0018).
The conventional RV metric with the strongest cor-
relation to 6-MWD was RVEF (r = 0.54, p = 0.0003)
and the strongest conventional LV metric was LVSV
(r = 0.39, p = 0.013). In addition, there was a signifi-
cant correlation between 6-MWD and E/A ratio (r = 0.39,
p = 0.013). When these metrics were inputted into a mul-
tiple linear regression analysis, only global Erad (β = 0.41,
p = 0.017) and lateral Srad (β = 0.33, p = 0.028) were inde-
pendent predictors of 6-MWD.
Relationship between myocardial velocity and clinical
worsening
All five patients who had operable proximal CTEPH
underwent subsequent thromboendarterectomy, and one
PAH patient was already receiving intravenous vasodila-
tor therapy at the time of CMR study. Clinical worsening
was studied in the remaining 34 patients. Over a median
follow-up period of 20 months (IQR 7.9 months), 8 pa-
tients were started on intravenous therapy and 1 died.
Metrics that predicted clinical worsening on univariate
cox regression analysis are shown in Additional file 2:
Fig. 2 Line graphs of global a radial, b longitudinal and c tangential LV velocities in a healthy volunteer (solid line) and a PH patient (dotted line).
The RR intervals for both subjects have been scaled to the same value for illustrative purposes. S, E and A waves are evident radially and longitudinally.
Biphasic systolic (S1 and S2) and early diastolic (E1 and E2) waves are observed tangentially. Cardiac cycles are normalized for heart rate for illustrative
purposes. Global Erad and Elong velocities are markedly reduced in PH. The tangential S2 wave is also reduced in PH. The reverse direction of untwisting
of biphasic early diastolic tangential waves was evident in all PH patients
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Table S2. The strongest predictive E wave myocardial
velocity was global Elong peak (6.3× increase in hazard
per SD reduction in the magnitude of the peak velocity).
The strongest conventional RV metric was RVEF (2.4×
increase in hazard per SD reduction in RVEF). In
addition, septal curvature was also predictive of clinical
worsening (3.6× increase in hazard per SD distortion of
septum towards the LV). Conventional LV metrics and
E/A ratio did not predict clinical worsening. When glo-
bal Elong peak, RVEF and SC were inputted into a
Fig. 4 Graphs demonstrating segmental variation in health (dotted line) and PH (— line) in a Erad time to peak, b Elong magnitude. a There is a
trend for an earlier Erad time to peak for the anterior segment in PH. There is no regional heterogeneity in Erad time to peak in health. b The anterior
and lateral walls had higher Elong peak velocities than the inferior wall and septum in health. Regional variation in the magnitude of Elong velocities is
less distinct in PH, with only the lateral segment having a tendency, albeit not statistically significant, for higher Elong velocities
Fig. 3 Velocity color maps for a radial, b longitudinal, and c tangential segmental LV motion from a healthy volunteer (top) and a PH patient
(bottom). The maps represent motion of sequential LV segments (y-axis) throughout the cardiac cycle (x-axis). The wave color (blue or red)
indicates direction of motion, with color intensity representing relative magnitude of the segmental velocity. There are segmental E wave
abnormalities in all components of motion: a Radially: In health, E wave timing is uniform throughout LV segments. In early diastole in PH, the anterior
segment tends to move outwards (Erad wave) first whilst the septum continues to move inwards. b Longitudinally: In health, peak
anterolateral segment Elong waves are of significantly greater magnitude, compared with only a trend for greater lateral segment Elong
waves in PH. c Tangentially: Reversal of E1 and E2 waves was observed in all patients
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multivariable cox regression model, only global Elong
was an independent predictor of clinical worsening
(p = 0.009).
Discussion
This is the first study to use TPM to assess LV myocar-
dial velocities in patients with PH. The main findings
were: i) Patients with PH had reduced global Erad and
Elong velocities, and reversal of both Etang waves; ii) Peak
global Erad velocity was an independent predictor of
6-MWD; and iii) Peak global Elong velocity was an in-
dependent predictor of clinical worsening. These re-
sults demonstrate that LV myocardial mechanics are
negatively affected by RV pressure overload and may
contribute to symptoms and clinical worsening.
LV myocardial velocities in PH
In keeping with previous studies, our results indicate
that PH is primarily associated with early diastolic LV
dysfunction [5, 8, 22]. Specifically, peak E wave velocities
were lower in patients compared to age and sex matched
controls. Importantly, LVSV was not an independent
predictor of E wave velocities. Thus, it is unlikely that
reduced pulmonary venous return is the main reason for
this finding. Interestingly, the only independent pre-
dictor of reduced E wave velocity was increased RVESV.
This suggests a link between RV dilation and LV dia-
stolic dysfunction, which we believe is mediated through
external constraint of the LV. It is easily understood that
LV filling can be reduced by abnormal septal dynamics
[9]. However, it is also possible that the pericardium also
plays an important part. As the RV dilates, the whole of
the pericardium becomes stretched and less compliant
[23, 24]. This could constrain the inferior and lateral LV
walls and additionally reduce LV filling. This idea is
backed up by animal studies of acute RV dilation,
where removal of the pericardium normalizes LV fill-
ing [25, 26]. The fact that the anterior segment is not
constrained by the pericardium or septum may ex-
plain the trend towards its earlier Erad peak, further
corroborating our hypothesis. The exact mechanism
underlying the reversal of the Etang peaks is not clear
from our results. A possible explanation might be the
significant geometric alterations seen in patients with
PH, but this requires further study.
It should be noted that these diastolic abnormalities
could be the result of LV remodeling and intrinsic
myocardial stiffening. This is particularly pertinent in
our patient population due to the high prevalence of
CTD, which is known to cause diastolic dysfunction
[27]. However, E wave velocities were similar across
etiological subgroups in our study, suggesting that the
results were not due to CTD-specific LV remodeling.
It is possible that PH itself could cause changes in
LV structure such as myocardial fibrosis or fiber re-
orientation [28]. Techniques such as T1 Mapping and
myocardial diffusion tensor imaging may be better placed
to determine if these factors are also important [29].
Functional correlates with myocardial velocities
We have shown that lower radial and longitudinal E
wave velocities are associated with reduced 6-MWD.
This is in keeping with E wave velocities being a marker
for diastolic dysfunction, which is known to limit aug-
mentation of stroke volume during exercise. In keeping
with the pivotal role of stroke volume, it is unsurprising
that resting LVSV also correlated with 6-MWD. How-
ever, global Erad was an independent predictor of 6-MWD
in a model adjusted for resting LVSV. This suggests that
resting Erad may be a better predictor of exercise stroke
volume augmentation than resting LVSV. In addition, the
lateral Srad peak was also predictive of 6-MWD. This is
interesting because the population Srad peaks were similar
in patients and controls. Nevertheless, patients did have
greater variance in Srad, which may explain the exercise
findings. The increased peak systolic velocity seen in some
Table 4 Correlations between abnormal global LV myocardial velocities in PH and hemodynamics
Erad Elong S2tang E1tang E2tang
r p-value r p-value r p-value r p-value r p-value
SC 0.40 0.01 0.33 0.041 −0.041 0.80 −0.24 0.13 0.13 0.43
mPAP −0.60 0.0005 −0.41 0.027 0.17 0.38 0.17 0.38 −0.19 0.32
PVR −0.47 0.011 −0.27 0.16 0.046 0.82 0.14 0.49 −0.16 0.43
RVEDV −0.26 0.11 −0.41 0.0087 0.0024 0.99 0.24 0.14 0.071 0.66
RVESV −0.45 0.004 −0.51 0.0007 0.030 0.86 0.35 0.023 0.062 0.71
RVSV 0.33 0.038 0.1006 0.54 −0.074 0.65 −0.17 0.29 0.040 0.81
LVEDV 0.34 0.035 0.13 0.43 0.083 0.61 −0.18 0.27 0.20 0.22
LVESV 0.061 0.71 −0.035 0.83 0.24 0.13 −0.093 0.57 0.29 0.067
LVSV 0.45 0.0032 0.22 0.18 −0.063 0.70 −0.20 0.23 0.077 0.64
E/A ratio 0.43 0.0077 0.38 0.019 −0.016 0.93 0.031 0.85 −0.0035 0.98
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patients is probably an attempt to maintain cardiac output
in the face of worsening disease. Conversely, the reduced
peak velocity found in other patients is possibly due to in-
trinsic LV systolic dysfunction or abnormal septal
interactions.
We also found that E wave velocities, in particular glo-
bal Elong, predicted clinical worsening. This is probably
because patients with impaired diastolic function have
less cardiac reserve and are therefore more symptomatic.
This increases the likelihood of up-titration of therapy
or death. The reasons why longitudinal rather than ra-
dial E wave is a better predictor of progression are not
obvious from our data. One possibility is that longitu-
dinal velocities might integrate more measures of cardiac
dysfunction than simply reduced LV filling. Importantly,
E/A ratio was similar in patients and controls and did
not independently predict 6-MWD or clinical worsening.
This demonstrates the benefits of TPM over conven-
tional measures of diastolic dysfunction.
In keeping with previous studies, RVEF did correl-
ate with 6-MWD and predicted clinical worsening [1].
However, RVEF was not an independent predictor of
exercise capacity in a model including global Erad, nor
was it an independent predictor of clinical worsening
in a model adjusted for global Elong. These results
suggest that reduced LV diastolic function may be
more important than RV function itself. This is con-
sistent with studies in patients with other forms of
RV pressure overload. For instance, in congenital
heart disease it has been shown that improved exer-
cise capacity after relief of RV outflow obstruction is
primarily due to better LV filling [9].
Assessing myocardial motion using imaging
We used TPM to assess myocardial mechanics. How-
ever, other CMR methods of assessing myocardial
motion do exist. These include tagging, strain encod-
ing (SENC) and displacement encoding with stimu-
lated echoes (DENSE) [30]. Although these techniques
have the benefit of measuring strain rather than vel-
ocity, they do have limitations. For instance, tagging
does not analyze through plane motion, while SENC
imaging is unable to measure radial strain. In con-
trast, high spatiotemporal resolution TPM allows the
measurement of simultaneous, multi-directional vel-
ocity encoded data acquired throughout the entire
cardiac cycle [12, 13]. This allows accurate analysis of
global and regional myocardial velocities and timing
parameters. Recently, it has been shown that it is
possible to acquire TPM data in a breath hold using
a spiral SENSE acquisition [31]. This opens up the
possibility of rapid acquisition of myocardial veloci-
ties, which would make this technique more clinically
feasible.
Limitations
Our feasibility study represents a single center experi-
ence of applying TPM to a small patient cohort. Further-
more, the low mortality in this population required a
more broadly defined composite outcome measure that
included transplant and intravenous therapy. Unfortu-
nately, such ‘soft’ outcome measures are more suscep-
tible to bias (although CMR was not used to make
clinical management decisions in this study). In addition,
the population was heterogeneous with a high number
of patients with CTD, possibly limiting the applicability
of the results to the majority of PH patients. Therefore,
this can only be considered a feasibility study demon-
strating that TPM data may be of clinical interest in this
group of patients. Nevertheless, the positive findings do
warrant further work in this area.
Other limitations include the fact that catheter
hemodynamic data was not available in all patients
and that formal tissue characterization was not per-
formed. In future studies, it will be vital that these
deficiencies are addressed.
A final important limitation is that RV TPM metrics
were not assessed in this study. It has been shown that
it is possible to assess RV TPM metrics using our tech-
nique [13]. However, a limitation of short axis TPM is
that it is not possible to correct for longitudinal bulk
motion. In the LV this is not a significant problem as
longitudinal bulk motion is limited. However, in severe
PH the RV displays a rocking motion that results in er-
rors in longitudinal velocity assessment [32]. Thus, as-
sessment of RV myocardial velocities would be better
achieved in the 4-chamber view and this would be im-
portant in future work.
Conclusions
Novel TPM by CMR is feasible in PH, permitting accurate
quantification of global and regional myocardial velocities.
TPM metrics of LV diastolic dysfunction in PH reliably
discriminate between health and disease, and are also
strongly predictive of functional capacity. TPM may also
be incrementally beneficial in identifying clinical worsen-
ing in PH compared with conventional CMR metrics of
RV function. These feasibility data support the application
of the technique to a larger group of patients over a longer
follow-up period. This would allow full determination of
the prognostic capacity of LV TPM metrics in PH. Future
work should also be directed at assessing the response of
these novel biomarkers to vasodilator therapy.
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